JP2021518348A5 - - Google Patents

Info

Publication number
JP2021518348A5
JP2021518348A5 JP2020549046A JP2020549046A JP2021518348A5 JP 2021518348 A5 JP2021518348 A5 JP 2021518348A5 JP 2020549046 A JP2020549046 A JP 2020549046A JP 2020549046 A JP2020549046 A JP 2020549046A JP 2021518348 A5 JP2021518348 A5 JP 2021518348A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020549046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052166 external-priority patent/WO2019180576A1/en
Publication of JP2021518348A publication Critical patent/JP2021518348A/ja
Publication of JP2021518348A5 publication Critical patent/JP2021518348A5/ja
Priority to JP2023172559A priority Critical patent/JP2024012300A/ja
Pending legal-status Critical Current

Links

JP2020549046A 2018-03-20 2019-03-18 医薬併用 Pending JP2021518348A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172559A JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645754P 2018-03-20 2018-03-20
US62/645,754 2018-03-20
PCT/IB2019/052166 WO2019180576A1 (en) 2018-03-20 2019-03-18 Pharmaceutical combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172559A Division JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Publications (2)

Publication Number Publication Date
JP2021518348A JP2021518348A (ja) 2021-08-02
JP2021518348A5 true JP2021518348A5 (https=) 2022-03-28

Family

ID=66251830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549046A Pending JP2021518348A (ja) 2018-03-20 2019-03-18 医薬併用
JP2023172559A Pending JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172559A Pending JP2024012300A (ja) 2018-03-20 2023-10-04 医薬併用

Country Status (14)

Country Link
US (1) US20210363254A1 (https=)
EP (1) EP3768717A1 (https=)
JP (2) JP2021518348A (https=)
KR (1) KR20200134253A (https=)
CN (1) CN111868088A (https=)
AU (2) AU2019240200B2 (https=)
BR (1) BR112020018755A2 (https=)
CA (1) CA3092307A1 (https=)
CL (1) CL2020002379A1 (https=)
IL (1) IL277334A (https=)
MX (1) MX2020009614A (https=)
RU (1) RU2020133811A (https=)
TW (1) TWI791794B (https=)
WO (1) WO2019180576A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017037579A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US20200261573A1 (en) * 2015-12-17 2020-08-20 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
WO2018185135A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Similar Documents

Publication Publication Date Title
JP2019517549A5 (https=)
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2019503349A5 (https=)
JP2020508317A5 (https=)
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
JP2021521205A5 (https=)
JP2014132009A5 (https=)
JP2012500180A5 (https=)
JP2021528423A5 (https=)
JP2024501471A5 (https=)
MX2015001627A (es) Terapia de combinacion para el tratamiento de glioblastoma.
JP2015500822A5 (https=)
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2021518348A5 (https=)
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
JP2023510199A5 (https=)
JP2025515092A5 (https=)
RU2020133811A (ru) Фармацевтические комбинации
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2023531090A5 (https=)
JP2023500480A5 (https=)
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor